|
The non-steroidal anti-inflammatory drug (NSAID) Diclofenac is in a class of
compounds delivered regionally or topically. Using various ViaDerm array
configurations, TransPharma demonstrated an ability to enhance skin penetration
of Diclofenac. These findings are applicable to a wide range of compounds, and
indicate the ability to reach target sites in various layers of the skin or
underlying tissues.
Non-steroidal anti-inflammatory drugs are widely used in treating muscle and
joint pain and are the fourth-largest class of drugs sold worldwide. Recent
market research shows that this market is growing at an annual rate of 18%. In
the U.S. alone, 22 million people are treated with NSAIDs annually for
rheumatoid arthritis and osteoarthritis. One of the leading NSAID at present is
diclofenac, a local anti-inflammatory drug, used to relieve pain in arthritic
and rheumatic conditions. The drug is administered either orally or topically in
a passive patch or cream. Oral delivery requires very high dosage in order for
the drug to reach a sufficient level in the body to provide pain relief to the
target area. This high dosage causes unpleasant adverse side effects. The cream
form has a very low dose efficiency resulting in a very limited therapeutic
effect.
A ViaDerm system for NSAIDs will offer a far more effective therapeutic
solution with increased local bioavailability.
TransPharma Medical has demonstrated the use of the NSAID molecule Diclofenac
in its ViaDerm platform.
Click here for Diclofenac In-Vitro Study
|
